LENSAR Inc. announced earlier this month (pdf) the closing of $27 million in PE financing.

LENSAR, headquartered in Orlando, Fla., is the developer of the LENSAR laser system for refractive laser-assisted cataract surgery.

Aisling Capital, Florida Growth Fund and Florida Opportunity Fund participated in the equity round.

The PE financing, along with up to $60 million in debt financing provided by new investor PDL BioPharma, will go toward supporting market expansion of the LENSAR system.